A medical cannabis company based in Latin America and Europe has announced significant new company milestones.
Khiron Life Sciences Corp. (Khiron) on Thursday announced that, as the first prescriptions for their full spectrum, high cannabidiol (CBD) medical cannabis are being filled in Peru, the company has now filled more than 3,000 prescriptions in Colombia.
The announcement comes after the Directorate General of Drug Supplies and Drugs (DIGEMID), Peru’s drug regulatory authority, granted Khiron authorization to fill medical cannabis prescriptions for Peruvian patients.
Khiron is the first company to sell medical cannabis in Peru and will distribute products through its agreement with Farmacia Universal, an established pharmacy chain with 10 locations in Lima.
While medicinal cannabis use has been legal in Peru since 2017, the country’s official medical cannabis program did not launch until December 2019, following the publication of key regulations and an announcement that imported medical cannabis had become available to citizens.
“After completing successfully all export, import and distribution requirements to bring our approved high CBD medical cannabis products into Peru,” says Khiron Peru Country Manager Luis Marquez. “We are now very proud to begin sales and give patients greater access to medical cannabis therapies in order to improve significantly their quality of life.”
Khiron reports that quotas for its high THC medical cannabis have gained approval from DIGEMID, and the company expects to begin filling prescriptions before the end of 2020.
Khiron CEO Alvaro Torres says that, despite the COVID-19 pandemic, the company has been able to continue to bring medical cannabis to patients, and is pleased to expand its reach and make prescriptions for its products available to the 32 million people who live in Peru.
Taking into account the size of Peru’s population, the country is expected to become one of the largest medical cannabis markets in South America.
